Nutrition

VISION HEALTHCARE ACQUIRES SVENSKT AND NEW CARE, LEADING PROVIDERS OF HIGH-QUALITY SUPPLEMENTS IN SWEDEN AND THE NETHERLANDS

NEW YORK, Nov. 20, 2025 /PRNewswire/ -- Vision Healthcare ("Vision"), a fast-growing European consumer healthcare platform, recently completed acquisitions of…

2 weeks ago

ESSE Care Welcomes Dr. Amanda Chu, Expanding Complex Minimally Invasive Surgery Offerings and Endometriosis Specialty Care 

With elite training in endometriosis excision and a commitment to whole-body, multidisciplinary care, Dr. Chu expands ESSE's mission of integrative,…

2 weeks ago

ESSE Care Welcomes Dr. Amanda Chu, Expanding Complex Minimally Invasive Surgery Offerings and Endometriosis Specialty Care 

With elite training in endometriosis excision and a commitment to whole-body, multidisciplinary care, Dr. Chu expands ESSE's mission of integrative,…

2 weeks ago

Best Tasting Protein Shake (2025): Ka’Chava Named Favorite Nutritional Shake by Expert Consumers

NEW YORK, Nov. 19, 2025 /PRNewswire/ -- Expert Consumers has named Ka'Chava as the top tasting protein shake of 2025,…

2 weeks ago

Gummi World Emerges as the Ideal U.S. Manufacturer as Gummy Product Brands and Retailers Face Rising Tariffs and Overseas Production Volatility

Rising tariffs, long lead times, and quality risks abroad are driving retailers toward Gummi World's highly certified U.S. production. CHANDLER,…

2 weeks ago

ADIA Nutrition Inc. to Host Webinar on HSCT for MS and Autoimmune Conditions with HSCT Warriors

Winter Park, Florida--(Newsfile Corp. - November 19, 2025) - ADIA Nutrition, Inc. (OTCQB: ADIA) invites all shareholders, supporters, and potential…

2 weeks ago

Protara Therapeutics Announces Positive Interim Results Demonstrating Robust Responses in the Ongoing Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations

80% of patients that completed treatment and 100% of patients that completed the eight-week response assessment achieved clinical successClinical success…

2 weeks ago

Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations on Wednesday, November 19, 2025

NEW YORK, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for…

2 weeks ago